At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 30 enrolled
Drug / intervention
Pembrolizumabdrug
Likely dose
Pembrolizumab 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Neoadjuvant Anti PD-1 Immunotherapy in Resectable Non-small Cell Lung Cancer [NEOMUN]
In Brief
A Phase 2 clinical trial evaluating Pembrolizumab for Non-small Cell Lung Cancer (NSCLC). Completed, enrolled 30 participants across 1 site.
Detailed Summary
NEOMUN is designed as an open-label, single arm, prospective, monocenter, phase II study of pembrolizumab in a neoadjuvant setting in patients with non-small cell lung cancer of Stage II/IIIA suitable for curative intent surgery.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-small Cell Lung Cancer (NSCLC)
CountriesGermany
CollaboratorsMerck Sharp & Dohme LLC
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedJun 2017
Enrollment StartJun 2018
Primary CompletionOct 2021
Study CompletionMay 2023
TodayJul 2026
First PostedJun 23, 2017
Enrollment StartJun 18, 2018
Primary CompletionOct 30, 2021
Study CompletionMay 5, 2023
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 9.0 years ago
Interventions
Pembrolizumabdrug
Pembrolizumab at fixed dose: 200 mg q3w i.v. for 2 cycles